Mantle Cell Lymphoma Articles

Rituximab Regimen Elicits High ORR in Relapsed MCL
Rory McCulloch, MD, discusses the results of a retrospective analysis looking at rituximab, bendamustine, and cytarabine in patients with mantle cell lymphoma who have relapsed on a BTK inhibitor.
Wang Explores Feasibility of CAR T Cells, Personalized Medicine in MCL
Michael Wang, MD, provides insight on recent advances in mantle cell lymphoma as well as research efforts for patients with a high risk of relapse.
Lisocabtagene Maraleucel Shows Promising Response Rates in Relapsed/Refractory MCL
The CAR T-cell therapy lisocabtagene maraleucel elicited a 71% overall response rate as well as a tolerable safety profile in a cohort of patients with relapsed/refractory mantle cell lymphoma.
Expert Makes Case for Frontline Targeted Therapy in Select MCL Subtypes
Ezzat Elhassadi, MD, highlights research being done to address the unmet need of patients with p53-mutant mantle cell lymphoma and the challenges faced in the current treatment paradigm.
Lead Investigator Shares Early Data With Ibrutinib Maintenance in MCL
Reem Karmali, MD, MS, shares early data with ibrutinib maintenance therapy and highlights recent advances and challenges in the treatment of patients with mantle cell lymphoma.
Pipeline Updates Advance Paradigms Across Lymphomas
Matthew S. McKinney, MD, discusses exciting treatment advances made in Hodgkin and non-Hodgkin lymphoma, specifically the compelling research in follicular lymphoma and mantle cell lymphoma.
MCL Landscape Rapidly Evolving With Promising Approaches on Horizon
Ann S. LaCasce, MD, MMSc, highlights recent progress made in MCL, exciting approaches under investigation, and provides insight into where future research should focus.
Small Molecule Shows Marked Activity Against Ibrutinib-Resistant MCL
Preclinical data suggest that the small molecule IACS-10759, which targets the oxidative phosphorylation (OXPHOS) and glutaminolysis pathways, may play a critical role in overcoming resistance to ibrutinib (Imbruvica) in mantle cell lymphoma.
MCL Treatment Paradigm Expands With Novel Combos
Timothy Fenske, MD, MS, discusses promising ongoing research in mantle cell lymphoma that will look to further advanced the evolving paradigm.
Clinical Outcomes Consistent in MCL Irrespective of Induction Regimen
Clinical outcomes were found to be consistent among transplant-eligible patients with mantle cell lymphoma, irrespective of the chemoimmunotherapy induction regimen that was administered.
Publication Bottom Border
Border Publication